Low hepatitis B surface antigen at baseline and increased ALT levels during treatment predicts significant HBsAg decline in peginterferon alfa added to long-term nucleus(t)ice analogue. Results from two randomized controlled trials in 165 patients
Farag, Mina, Choi, Hannah S.J., Fung, Scott, Chi, Heng, van Campenhout, Margo J.H., Liem, Seng, Xie, Qing, Sonneveld, Milan, Wong, David, Feld, Jordan, van Erpecum, Karel J., De Man, Robert, Hansen, BVolume:
73
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(20)32195-4
Date:
August, 2020
File:
PDF, 471 KB
2020